Insulin oral - Oshadi Drug Administration

Drug Profile

Insulin oral - Oshadi Drug Administration

Alternative Names: Oshadi Icp

Latest Information Update: 16 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oshadi Drug Administration
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 16 Feb 2016 Phase-II development is still ongoing in Israel (NCT01973920)
  • 18 Dec 2013 Phase-II clinical trials in Type-1 diabetes mellitus in Israel (PO)
  • 27 Oct 2013 Oshadi Drug Administration plans a phase II trial for Type-1 diabetes mellitus in Israel (NCT01973920)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top